Publicaciones (204) Publicaciones de María José García Sánchez

2024

  1. Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

    Therapeutic Advances in Gastroenterology, Vol. 17

  2. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74

  3. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study

    United European Gastroenterology Journal

  4. Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply

    Alimentary Pharmacology and Therapeutics

  5. Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

    Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259

  6. Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 3

  7. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease

    Digestive and Liver Disease, Vol. 56, Núm. 3, pp. 468-476

  8. Serum and Urine Metabolomic Profiling of Newly Diagnosed Treatment-Naïve Inflammatory Bowel Disease Patients

    Inflammatory Bowel Diseases, Vol. 30, Núm. 2, pp. 167-182

2023

  1. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: An international multicentre analysis

    CMAJ. Canadian Medical Association Journal, Vol. 66, Núm. 3, pp. E310-E320

  2. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  3. Idiopathic Thrombocytopaenic Purpura associated with Inflammatory Bowel Disease: a multicentre ECCO CONFER case series

    Journal of Crohn's and Colitis, Vol. 17, Núm. 5, pp. 722-727

  4. Increased risk of MAFLD and Liver Fibrosis in Inflammatory Bowel Disease Independent of Classic Metabolic Risk Factors

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 2, pp. 406-414.e7

  5. Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

    British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294

  6. Profiling the immune landscape in mucinous ovarian carcinoma

    Gynecologic Oncology, Vol. 168, pp. 23-31

  7. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  8. Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review

    Journal of Crohn's and Colitis, Vol. 17, Núm. 6, pp. 972-994

  9. Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review

    Journal of Clinical Medicine, Vol. 12, Núm. 23

  10. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

    Journal of Pathology: Clinical Research, Vol. 9, Núm. 3, pp. 208-222

2022

  1. Aportación de la farmacocinética al tratamiento con fenobarbital: aplicación a algunos casos clínicos

    Farmajournal, Vol. 7, Núm. 1, pp. 83-91

  2. CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

    Cancers, Vol. 14, Núm. 2